Raymond James Maintains Strong Buy on Blueprint Medicines, Raises Price Target to $100
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Dane Leone has reaffirmed a Strong Buy rating on Blueprint Medicines (NASDAQ:BPMC) and increased the price target from $85 to $100, indicating a positive outlook on the company's stock.
December 22, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James analyst reaffirms a Strong Buy rating on Blueprint Medicines and raises the price target to $100, suggesting a bullish stance on the stock.
The increase in price target by a reputable analyst typically signals a strong conviction in the company's future performance and can lead to increased investor confidence, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100